GlassScriptPhysician profile
Karim H Romman
NPI 1003971755
$1,033.02
in general payments reported to CMS, 2019-2025
14 companies · $290 in 2025
The $290 reported for 2025 was more than what 84% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $36.93 · 2020: $28.89 · 2021: $81.15 · 2022: $183 · 2023: $224 · 2024: $189 · 2025: $290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $703.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $702.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cranial Technologies, INC | $226.25 | 2019-2025 | Doc Band |
| Glaxosmithkline, LLC. | $213.43 | 2022-2025 | Bexsero, Pediarix, Rotarix |
| Cumberland Pharmaceuticals, INC. | $204.71 | 2019-2025 | Kristalose |
| Sanofi Pasteur INC. | $94.71 | 2022-2025 | |
| Cipher Pharmaceuticals US LLC | $59.21 | 2025 | Spinosad, Natroba |
| Merck Sharp & Dohme LLC | $54.77 | 2022-2025 | Enflonsia |
| Pfizer INC. | $44.49 | 2021-2024 | |
| Sanofi-Aventis U.S. LLC | $36.51 | 2024-2025 | |
| Seqirus USA INC | $18.40 | 2024 | Flucelvax |
| Sarepta Therapeutics, INC. | $17.92 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $16.28 | 2024 | Flumist Quadrivalent |
| Tempus Ai, INC | $16.01 | 2025 | Tempus Pixel |
| Phadia US INC. | $15.47 | 2025 | Immunocap |
| Kowa Pharmaceuticals America, INC. | $14.86 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karim Romman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.